• Barbara Malawska and Katarzyna Kulig.
• Jagiellonian University Medical College, Department of Physicochemical Drug Analysis, 30-688 Kraków, Medyczna 9, Poland. mfmalaws@cyf-kr.edu.pl
• Expert Opin Investig Drugs. 2008 Mar 1; 17 (3): 361-9.

BackgroundEpilepsy is a neurological disorder with a worldwide prevalence estimated to be 0.5-1.0% of the population. Many potent antiepileptic drugs (AED) have been used for treatment but still about 30% of patients are resistant to current AEDs. Some AEDs are also used for the treatment of neuropathic pain.ObjectiveThe aim of this report is to present preclinical and clinical studies of brivaracetam (UCB-34714), a new drug developed by UCB Pharma.MethodsPublished results of preclinical studies in several animal models of epilepsy, neuropathic pain, essential tremor and results of Phase I and II evaluations of brivaracetam have been analysed.Results/ConclusionBrivaracetam represents a new mechanism of action being a ligand of synaptic vesicle protein 2A. It is undergoing Phase III evaluation after a successful Phase II programme in which was effective as an adjunctive treatment in partial-onset epilepsy (50 mg/day). It is well tolerated, without serious adverse side effects.

25 keywords...

hide…